Caprock Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Caprock Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,988	Closed	-$365K	–	579
2021 Q2	$365K	Sell	1,988 -85	-4%	-$14.6K	0.03%	312
2021 Q1	$317K	Buy	2,073 +50	+2%	+$7.73K	0.03%	321
2020 Q4	$316K	Buy	+2,023	New	+$260K	0.04%	313
2019 Q1	–	Sell	-2,463	Closed	-$240K	–	409
2018 Q4	$240K	Buy	+2,463	New	+$291K	0.06%	280

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Caprock Group's ALXN Position: Q3 2021 in Review

Caprock Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,988 shares — an estimated $365K sold.

Caprock Group first reported a position in ALXN in Q4 2018 and held it in 4 quarters. The position peaked at $365K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Caprock Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Caprock Group sold 1,988 Alexion Pharmaceuticals shares in Q3 2021, an estimated $365K.
Caprock Group first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 4 quarters.
Caprock Group's Alexion Pharmaceuticals position peaked at $365K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Caprock Group's 13F filing for Q3 2021, filed 7 Oct 2021.